Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report

Journal of Translational Medicine

Giuseppe Castaldo¹  Olga Scudiero⁴  Rosanna Di Fiore⁴  Anna Lucania²  Amalia De Renzo²  Alferio Niglio³  Pierpaolo Di Micco³ 

[1] Facoltà di Scienze, Università del Molise, Aesernia, Italy;Divisione di Ematologia, Università di Napoli "Federico II", Naples, Italy;Divisione di Medicina Interna, Seconda Università di Napoli, Naples, Italy;Dipartimento di Biochimica e Biotecnologie Mediche e CEINGE-Bioteconologie avanzate, Università di Napoli "Federico II", Naples, Italy

关键词: G-CSF;    central venous catheters;    PTHRA₂₀₂₁₀G;    FVL;    MTHFR_C677T;    Hodgkin's disease;    non-Hodgkin lymphoma;    LEDVT;    molecular markers UEDVT;    malignancy;    acquired thrombophilia;    inherited thrombophilia;   

Others  :  1208555
DOI  :  10.1186/1479-5876-2-7

 received in 2004-01-03, accepted in 2004-03-22,  发布年份 2004

【 摘 要 】

Background

Congenital thrombotic risk factors, oncological diseases and its therapies have been related to an increased occurrence of upper extremities deep venous thrombosis (UEDVT).

Patients and methods

We studied seven patients bearing lymphoma (one Hodgkin's and six non-Hodgkin's) who developed UEDVT, one at diagnosis and six during chemotherapy (two of these six cases had implantation of a central venous catheter and four received Growth Colony Stimulating Factors in addition to chemotherapy). Patients were screened for: factor V G1691A (Leiden), prothrombin G20210A, methylene tetrahydrofolate reductase (MTHFR) C677T mutations and antithrombin III, proteins C and S plasma activity.

Results

All patients were wild-type homozygotes for G20210A. One was heterozygote for factor V G1691A, the other 6 were wild-type homozygotes. Three of the 7 patients were homozygotes and 2 heterozygotes for the MTHFR mutation; the remaining 2 were wild-type homozygotes. Clotting inhibitor levels were normal in all patients.

Conclusions

UEDVT in patients bearing haematological malignancies can occur irrespective of congenital thrombophilic alterations. However, in a subgroup of patients UEDVT could also depend on congenital thrombophilic alterations. A screening for inherited thrombophilia can identify high risk patients that could be specifically treated to prevent thrombotic complications.

【 授权许可】

   
2004 Di Micco et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Balbarini A, Rugolotto M, Buttitta F, Mariotti R, Strata G, Mariani M: Deep venous thrombosis: epidemiologic, diagnostic and therapeutic aspects. Cardiologia 1998, 43:605-615.
• [2]Girolami A, Prandoni P, Zanon E, Bagatella P, Girolami B: Venous thromboses of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs. Blood Coagul Fibrinolysis 1999, 10:455-457.
• [3]Niglio A, Torella R, Izzo T, Viggiano G, Di Micco P: Inquadramento clinico diagnostico delle trombosi venose profonde degli arti superiori. Haematologica 2003, 88(Suppl 7):S17-S18.
• [4]Falanga A: Tumor cell prothrombotic properties. Haemostasis 2001, 31(Suppl 1):1-4.
• [5]Ottinger H, Belka C, Kazole G, Engelhard M, Meusers P, Paar D, Metz KA, et al.: Deep venous thrombosis and pulmonary artery embolism in high grade non-Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995, 54:186-194.
• [6]Ruggeri M, Castaman G, Tosetto A, Rodeghiero F: Low prevalence of thrombophilic coagulation defects in patients with deep vein thrombosis of upper limb. Blood Coagul Fibrinolysis 1997, 8:191-194.
• [7]Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci PM: Risk factors for deep venous thrombosis of upper extremities. Ann Intern Med 1997, 126:707-711.
• [8]Prandoni P, Bernardi E: Upper extremity deep vein thrombosis. Curr Opin Pulm Med 1999, 5:222-226.
• [9]Prescott MS, Tikoff G: Deep venous thrombosis of upper extremity: a reappraisal. Circulation 1979, 59:350-355.
• [10]Monreal M, Davant E: Thrombotic complications of central venous catheters in cancer patients. Acta Haematol 2001, 106:69-72.
• [11]Di Micco P, Niglio A, Chirico G, Russo F, Izzo T, Castaldo G, D'Uva M, et al.: Significant reduction of free S protein in women receiving chemoendocrine adjuvant therapy for breast cancer based on intravenous CMF administration and oral tamoxifen. Exp Oncol 2002, 24:301-304.
• [12]Souto JC: Search for new thrombosis related genes through intermediate phenotypes. Genetic and household effects. Pathophysiol Haemost Thromb 2002, 32:338-340.
• [13]Hingorani A, Ascher E, Hanson J, Scheinman M, Yorkovich W, Lorenson E, De Pippo P, Salles-Cunha S: Upper extremity versus lower extremity deep venous thrombosis. Am J Surg 1997, 174:214-217.
• [14]Prandoni P, Polistena P, Bernardi E, Cogo A, Casara D, Verlato F, Angelini F, et al.: Upper-extremity deep vein thrombosis. Risk factors, diagnosis and complications. Arch Intern Med 1997, 157:57-62.
• [15]Lensing AW, Prandoni P, Prins NH, Buller HR: Deep-vein thrombosis. Lancet 1999, 353:479-485.